[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20084533L - Pyrimidin-derivat som PI3K-inhibitor og bruk av dette - Google Patents

Pyrimidin-derivat som PI3K-inhibitor og bruk av dette

Info

Publication number
NO20084533L
NO20084533L NO20084533A NO20084533A NO20084533L NO 20084533 L NO20084533 L NO 20084533L NO 20084533 A NO20084533 A NO 20084533A NO 20084533 A NO20084533 A NO 20084533A NO 20084533 L NO20084533 L NO 20084533L
Authority
NO
Norway
Prior art keywords
pi3k inhibitor
pyrimidine derivative
pyrimidine
derivative
pi3k
Prior art date
Application number
NO20084533A
Other languages
English (en)
Other versions
NO342978B1 (no
Inventor
Nobuo Shimma
Jun Ohwada
Hirosato Ebiike
Hatsuo Kawada
Kenji Morikami
Mitsuaki Nakamura
Miyuki Yoshida
Nobuya Ishii
Masami Hasegawa
Shun Yamamoto
Kohei Koyama
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084533(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20084533L publication Critical patent/NO20084533L/no
Publication of NO342978B1 publication Critical patent/NO342978B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20084533A 2006-08-08 2008-10-28 Pyrimidin-derivat som PI3K-inhibitor og bruk av dette NO342978B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006216108 2006-08-08
JP2007118631 2007-04-27
PCT/JP2007/065396 WO2008018426A1 (fr) 2006-08-08 2007-08-07 Dérivé de pyrimidine comme inhibiteur de la PI3K et son utilisation

Publications (2)

Publication Number Publication Date
NO20084533L true NO20084533L (no) 2009-01-09
NO342978B1 NO342978B1 (no) 2018-09-17

Family

ID=39032956

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084533A NO342978B1 (no) 2006-08-08 2008-10-28 Pyrimidin-derivat som PI3K-inhibitor og bruk av dette

Country Status (26)

Country Link
US (1) US8022205B2 (no)
EP (1) EP2050749B1 (no)
JP (1) JP4450857B2 (no)
KR (1) KR101435692B1 (no)
AR (1) AR062292A1 (no)
AU (1) AU2007282535B9 (no)
BR (1) BRPI0714908B8 (no)
CA (1) CA2659604C (no)
CL (1) CL2007002316A1 (no)
CY (1) CY1119882T1 (no)
DK (1) DK2050749T3 (no)
ES (1) ES2657635T3 (no)
HU (1) HUE035116T2 (no)
IL (1) IL196601A (no)
LT (1) LT2050749T (no)
MX (1) MX2009001451A (no)
MY (1) MY145385A (no)
NO (1) NO342978B1 (no)
NZ (1) NZ575274A (no)
PE (1) PE20080527A1 (no)
PL (1) PL2050749T3 (no)
PT (1) PT2050749T (no)
RU (1) RU2448109C2 (no)
SI (1) SI2050749T1 (no)
TW (1) TWI394758B (no)
WO (1) WO2008018426A1 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2125822T3 (en) * 2006-12-21 2015-01-12 Nerviano Medical Sciences Srl SUBSTITUTED PYRAZOLOQUINAZOLINDERIVATER, process for their preparation and their use as kinase inhibitors
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK3289876T3 (da) * 2008-06-16 2022-10-10 Univ Tennessee Res Found Forbindelser til behandling af cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US8513221B2 (en) * 2008-07-07 2013-08-20 Xcovery Holding, LLC PI3K isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
ES2539478T3 (es) * 2008-11-11 2015-07-01 Xcovery Holding Company Llc Inhibidores de PI3K/mTOR cinasa
BRPI0918337A2 (pt) * 2008-12-19 2017-05-30 Abbott Lab composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso
NZ595372A (en) 2009-03-27 2013-11-29 Vetdc Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
ES2706185T3 (es) 2009-07-07 2019-03-27 Mei Pharma Inc Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer
EP2475375A4 (en) * 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CN104592205A (zh) 2010-03-01 2015-05-06 Gtx公司 用于治疗癌的化合物
JP2013529212A (ja) * 2010-05-19 2013-07-18 エクスカバリー ホールディング カンパニー，エルエルシー ｍＴＯＲ選択的キナーゼ阻害剤
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
MX2013015147A (es) * 2011-07-05 2014-03-27 Vertex Pharma Procesos y compuestos intermediarios para producir azaindoles.
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
DK2751109T3 (en) 2011-09-02 2017-01-23 Incyte Holdings Corp HETEROCYCLYLAMINES AS PI3K INHIBITORS
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
KR20150009540A (ko) 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
PL2868660T3 (pl) * 2012-07-02 2018-05-30 Taiho Pharmaceutical Co., Ltd. Środek wzmacniający działanie przeciwnowotworowe zawierający związek imidazooksazynowy
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
BR112015010035A2 (pt) * 2012-11-01 2017-07-11 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
CN103588792B (zh) 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
LT3421468T (lt) 2013-11-13 2021-01-11 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitorių paruošimo būdai
US10683550B2 (en) 2014-04-04 2020-06-16 Crown Bioscience, Inc. (Taicang) HNF4G-RSPO2 fusion gene and use thereof in treatment of cancer
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
RS63963B1 (sr) 2015-02-27 2023-03-31 Incyte Holdings Corp Postupak pripreme pi3k inhibitora
JPWO2016136928A1 (ja) 2015-02-27 2017-08-31 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SI3458067T1 (sl) 2016-05-18 2021-07-30 Torqur Ag Zdravljenje nevroloških obolenj
WO2018007331A1 (en) 2016-07-08 2018-01-11 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
EP3484884B1 (en) 2016-07-14 2021-01-27 Hoffmann-La Roche AG Fused pyrimidine derivatives
IT201600092469A1 (it) * 2016-09-14 2018-03-14 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Blonanserina
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
EP3523304B1 (en) 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Bicyclic heteroaryl derivatives
PL3618875T3 (pl) 2017-05-02 2023-10-23 Novartis Ag Terapia skojarzona obejmująca inhibitor raf i trametynib
CN110996959A (zh) 2017-05-23 2020-04-10 梅制药公司 联合疗法
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
US11414420B2 (en) 2017-11-27 2022-08-16 Hoffmann-La Roche Inc. Pyrimidine derivatives
US20230271965A1 (en) * 2020-06-03 2023-08-31 Kineta, Inc. Bicyclic heteroarenes and methods of their use
TW202220661A (zh) 2020-08-07 2022-06-01 德商柏林化學股份公司 包含pi3k抑制劑之經改良醫藥調配物
CA3215002A1 (en) 2021-04-09 2022-10-13 Christian Gege Deuterated dhodh inhibitors
MX2024007009A (es) * 2021-12-08 2024-08-22 Kineta Inc Heteroarenos bicíclicos y métodos para su uso.
MX2024007010A (es) * 2021-12-08 2024-08-26 Kineta Inc Pirimidinas y metodos para su uso.
WO2024023766A1 (en) 2022-07-28 2024-02-01 Berlin-Chemie Ag P13k inhibitor combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325268A (ja) 1986-02-24 1996-12-10 Mitsui Petrochem Ind Ltd ピロロ〔３，４−ｄ〕ピリミジン誘導体
EP0257102B1 (en) 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
CA2067221C (en) * 1989-10-11 1997-04-15 Yasuji Sakuma Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US7384937B2 (en) * 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
RU2328497C2 (ru) 2003-05-05 2008-07-10 Ф.Хоффманн-Ля Рош Аг Конденсированные производные пиримидина и лекарственное средство, обладающее активностью в отношении crf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
JPWO2008018426A1 (ja) 2009-12-24
BRPI0714908B1 (pt) 2020-10-13
PT2050749T (pt) 2018-01-02
NZ575274A (en) 2010-11-26
BRPI0714908B8 (pt) 2021-05-25
IL196601A (en) 2015-03-31
EP2050749B1 (en) 2017-11-22
KR20090047462A (ko) 2009-05-12
EP2050749A1 (en) 2009-04-22
CA2659604A1 (en) 2008-02-14
AR062292A1 (es) 2008-10-29
CA2659604C (en) 2015-04-28
MY145385A (en) 2012-01-31
EP2050749A4 (en) 2011-03-30
US8022205B2 (en) 2011-09-20
CY1119882T1 (el) 2018-06-27
AU2007282535B2 (en) 2013-05-30
TW200817411A (en) 2008-04-16
CL2007002316A1 (es) 2008-02-01
KR101435692B1 (ko) 2014-09-01
RU2448109C2 (ru) 2012-04-20
AU2007282535A1 (en) 2008-02-14
DK2050749T3 (en) 2018-01-08
BRPI0714908A2 (pt) 2013-05-28
NO342978B1 (no) 2018-09-17
ES2657635T3 (es) 2018-03-06
US20100069629A1 (en) 2010-03-18
AU2007282535B9 (en) 2013-06-20
IL196601A0 (en) 2009-11-18
TWI394758B (zh) 2013-05-01
LT2050749T (lt) 2018-01-10
PL2050749T3 (pl) 2018-03-30
JP4450857B2 (ja) 2010-04-14
HUE035116T2 (hu) 2018-05-02
RU2009108328A (ru) 2010-09-20
MX2009001451A (es) 2009-02-18
PE20080527A1 (es) 2008-07-09
SI2050749T1 (en) 2018-04-30
WO2008018426A1 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
NO20084533L (no) Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
DK2049557T3 (da) 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
NO20091423L (no) Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
DK2277509T3 (da) DPP IV inhibitorformuleringer
DK2402317T3 (da) DGAT-inhibitor
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK1981892T3 (da) Thienopyridinderivater som mek-inhibitorer
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2125748T3 (da) Acylaminopyrazol som FGFR inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
BRPI0716781A2 (pt) Inibidores da quinase
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
ATE483711T1 (de) Spiroindolinonderivate
NO20084764L (no) Tioksantinderivater og deres anvendelse som MPO inhibitorer
ATE469905T1 (de) Pyridopyrimidinonderivate
DK2439205T3 (da) Carboxamidforbindelser og deres anvendelse som calpaininhibitorer